


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

1-14. (Cancelled)

15. (Previously presented) A compounds with a general formula (I)



in which



m is the number 0 or 1;

Z and Z' are an integer ranging from 0 to 2 when they are different or are an integer ranging from 1 to 2 when they are the same;

Y and Y', which can be the same or different, are $(CH_2)_{n1}$; $(CH_2)_{n2}-CH[NR^{VII}(CH_2)_{n4}-NHR^I]-$
 $(CH_2)_{n3}$; $CH_2-CH[CH_2-CH_2]_2-$ or $(CH_2)_{n2}-N[(CH_2)_{n4}-NHR^{IV}]-CH_2$;

Y" is selected from the group consisting of H; cycloalkyl C3-C7; $(CH_2)_{n5}-N[CH_2-CH_2]_2N-$
 $(CH_2)_{n6}NHR^V$; $(CH_2)_{n7}CH[CH_2-CH_2]_2NR^V$;

X is O, or is a simple bond;

n-n7, which can be the same or different, are an integer ranging from 0 to 5;

R^I , R^{II} , R^{III} , R^{IV} , and R^V , which can be the same or different, are a protective group for the
nitrogen to which they are bound; CO_2R^{VI} ; CO_2CH_2Ar ; $CO_2(9\text{-fluorenylmethyl})$; $(CH_2)_{n5}-$
 $NHCO_2R^{VI}$; CH_2Ar ; $COAr$; $(CH_2)_{n5}-NHCO_2CH_2Ar$; $(CH_2)_{n5}-NHCO_2-(9\text{-fluorenylmethyl})$.

R^{VI} is a straight or branched (C_1 - C_6) alkyl;

R^{VII} is H or R^I-R^V ;

Ar is a C_6 - C_{12} aromatic residue, phenyl, optionally substituted with one or more groups selected
from: halogen, hydroxy, C_1 - C_5 alkyl, C_1 - C_5 alkoxy, phenyl, cyano, nitro, $-NR^{VIII}R^{IX}$, where R^{VIII}
and R^{IX} , which can be the same or different, are hydrogen, straight or branched (C_1 - C_5) alkyl, or
Ar is a heterocyclic group, said heterocyclic group containing at least one heteroatom selected
from a nitrogen atom, optionally substituted with a (C_1 - C_5) alkyl group, and/or oxygen and/or
sulphur; said heterocycle can be substituted with one or more groups selected from halogen,
hydroxy, C_1 - C_5 alkyl, C_1 - C_5 alkoxy, phenyl, cyano, nitro,

$-NR^{VIII}R^{IX}$, where R^{VIII} and R^{IX} , which can be the same or different, are hydrogen, straight or
branched (C_1 - C_5) alkyl, the N1-oxides, racemic mixtures, their individual enantiomers, their
individual diastereoisomers, the E and Z forms, their mixtures, and pharmaceutically acceptable
salts.

16. (Previously presented) A compound according to claim 15, in which the protective
groups are bulky groups of a lipophilic nature.

17. (Previously presented) A compound according to claim 15, in which the protective groups are selected from the group consisting of: $\text{CO}_2\text{R}^{\text{VI}}$; $\text{CO}_2\text{CH}_2\text{Ar}$; CO_2 -(9-fluorenylmethyl); $(\text{CH}_2)_{n5}\text{-NH CO}_2\text{R}^{\text{VI}}$; $(\text{CH}_2)_{n5}\text{-NHCO}_2\text{CH}_2\text{Ar}$; $(\text{CH}_2)_{n5}\text{-NHCO}_2$ -(9-fluorenylmethyl), in which R^{VI} is as defined above.

18. (Previously presented) A compound according to claim 17, in which the protective groups are selected from the group consisting of tert-butoxycarbonyl; benzyloxycarbonyl; 9-fluorenylmethyloxycarbonyl.

19. (Previously presented) A compound according to claim 15, in which m is 0.

20. (Currently amended) A compound according to claim 19, selected from the group consisting of:

tert-butylester of 20S-(4-{[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylaminopropyl)-carbamic acid;

tert-butylester of 20S-(4-{[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-carbamic acid; and

~~tert-butylester of 20S-[3-(7-camptothecinylidene-amino)-butyl]-carbamic acid;~~

~~20S-7-[3-(N-tert-butoxycarbonylaminopropoxyimino-methyl)-camptothecin-~~

~~benzyl ester of 20S-(4-{[3-(7-camptothecinylidene-amino)-propyl]-benzyloxycarbonyl-amino}-butyl)-carbamic acid.~~

21. (Previously presented) A compound according to claim 15, in which m is 1.

22. (Currently amended) A compound according to claim 21, selected from the group consisting of:

tert-butylester of 20RS-(4-{[3-(7-homocamptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylaminopropyl)-carbamic acid;

tert-butylester of 20RS-(4-{[3-(7-homocamptothecinylidene-amino)-propyl]-

tertbutoxycarbonyl-

amino}-butyl)-carbamic acid; and

~~tert-butylester of 20RS-[3-(7-homocamptothecinylidene-amino)-butyl]-carbamic acid;~~

~~20R,S-7-[3-(N-tert-butoxycarbonylamino)propoxyimino-methyl]-Homocamptothecin.~~

benzyl ester of 20S-(4-{[3-(7-homocamptothecinylidene-amino)-propyl]-benzyloxycarbonyl-
amino}-butyl)-carbamic acid.

23. (Previously presented) A pharmaceutical composition containing at least one compound according to claim 15 as the active ingredient in admixture with at least one pharmaceutically acceptable vehicle and/or excipient.
24. (Previously presented) A method of inhibiting topoisomerase comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.
25. (Previously presented) A method of treating cancer comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.
26. (Previously presented) A method of combating parasites comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.
27. (Currently amended) A method of treating a virus disease comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.
28. (New) The method according to claim 25 wherein said cancer is lung cancer, non-microcytoma lung cancer, colorectal cancer, gastric cancer, prostate cancer or glioma.
29. (New) The method according to claim 25 wherein said cancer is non-microcytoma lung cancer or gastric cancer.